Compare prices and buy SLU-PP-915 from 4 research peptide vendors - also called suppliers or sources. Updated daily.
SLU-PP-915 is a small-molecule pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, not a peptide. It is a boronic acid drawn from a thiophene series designed to keep ERR agonist activity while resisting metabolic breakdown, and in rodents it upregulates the ERR target genes that govern mitochondrial biogenesis and oxidative metabolism. Its developers report it is active when given by mouth, which distinguishes it from the earlier pan-ERR agonist SLU-PP-332. It is catalogued alongside the mitochondrial compounds by commercial overlap rather than chemical kinship, its research record is preclinical, and it holds no FDA approval.
For research purposes only. Not medical advice.
SLU-PP-915 is a small molecule, not a peptide. It is a boronic acid, [3-[5-[(2-fluorophenyl)carbamoyl]thiophen-2-yl]phenyl]boronic acid (C17H13BFNO3S, formula weight about 341), catalogued here alongside the mitochondrial compounds because of commercial overlap rather than chemical kinship.
Like SLU-PP-332, it is a pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, the orphan nuclear receptors that bind no endogenous estrogen and that drive the transcriptional program for mitochondrial biogenesis and oxidative metabolism. That receptor biology, and the laboratory meaning of the term "exercise mimetic" as applied to this class, are set out on the SLU-PP-332 page.
What is specific to this compound is its chemistry. Hampton and colleagues reported it in the European Journal of Medicinal Chemistry in 2023, starting from the known acyl hydrazide template and the agonist GSK-4716 and using structure-based design to build 2,5-disubstituted thiophenes, with direct binding to ERRgamma confirmed by proton NMR. The decisive step was replacing the phenol or aniline group with a boronic acid, which held activity while improving metabolic stability in microsomal assays, and profiling showed roughly equivalent activity at ERRalpha and ERRbeta, giving the pan-agonist profile. SLU-PP-915 significantly upregulated ERR target genes including the PGC-1alpha coactivator, lactate dehydrogenase A, DNA damage inducible transcript 4 and pyruvate dehydrogenase kinase 4, in cells and in animals.
The reason the boronic acid matters is a limitation of the earlier compound. SLU-PP-332's developers state that it lacks oral bioavailability, which the SLU-PP-332 page covers along with the injected route its rodent studies used. The thiophene boronic acid series was built for stability, and Billon, Appourchaux, Cote and Burris then reported oral activity for this molecule directly, in a Journal of Pharmacology and Experimental Therapeutics paper titled "An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity", published in the journal's January 2026 issue. The two compounds have also been studied together in a cardiac model, described on the SLU-PP-332 page.
All of this is cell-culture and animal work. There is no published human study of SLU-PP-915.
The compound has been characterized by an anti-doping laboratory, the step that precedes routine screening for it. Moller, Krug and Thevis published in Rapid Communications in Mass Spectrometry in 2026 a mass spectrometric characterization of both pan-ERR agonists together with their in vitro metabolic fate in human liver preparations. The two behaved differently: SLU-PP-332 yielded nine metabolites, six Phase-I and three Phase-II, while SLU-PP-915 yielded seven, all Phase-I. Three of the SLU-PP-915 metabolites were confirmed by chemical synthesis and NMR, and the authors synthesized a chlorinated analog of the compound for use as an internal standard. They noted that no metabolism study of SLU-PP-915 had been published before theirs, and framed the work as preemptive, characterizing such compounds before they reach the market.
No regulator has approved the compound. Drugs@FDA lists no approved product containing it and ClinicalTrials.gov returns no registered study, both read on November 4, 2026. Because it is a small molecule rather than a peptide, it also sits outside the compounding proceedings that shape much of this catalog: it appears on neither table of the FDA's Category 2 bulk drug substances page, on neither the 503A nor the 503B nomination category list, and in no FDA warning letter, all read on November 4, 2026, and it was absent from the July 2026 Pharmacy Compounding Advisory Committee agenda. The patent covering its chemical series is licensed to a company two of the senior authors co-founded.
In sport it is prohibited by name from January 1, 2027. The World Anti-Doping Agency's 2027 Prohibited List lists "SLU-PP-332, SLU-PP-915 and related substances" among the metabolic modulators in section S4.4.1. The 2026 list names no ERR agonist, so until the 2027 list takes effect the compound is caught by section S0, which prohibits at all times any substance holding no current approval by a governmental health authority.
This row carries no CAS Registry Number, deliberately. A number circulates in supplier listings and as an uncurated synonym on the compound's PubChem record, but no curated registry pairs it with this structure, so PeptideScouter verifies identity against the molecular formula and the PubChem compound record instead.
Vendor titles compress the name, with "SLU-PP-915" and "SLU-PP915" in product titles and the shorter "slu-915" in product URLs. The prefix records where the series was made, at Saint Louis University. One caution follows from that: a listing titled only "SLU-PP", naming no molecule on its product page or its certificate of analysis, is not indexed here, because the prefix alone does not establish which compound is in the bottle.
The compound reaches this market in capsules rather than lyophilized vials, so its listings carry no per-milligram figure.
No. It is a small molecule, a boronic acid built on a thiophene scaffold, with the formula C17H13BFNO3S and a formula weight of about 341. Peptides are chains of amino acids. It is catalogued on PeptideScouter because research vendors sell it beside mitochondrial and metabolic peptides, not because it is chemically related to them.
They act on the same receptors but are different molecules. Both are pan-agonists of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma. SLU-PP-332 is an acyl hydrazone, and its developers state it lacks oral bioavailability, which is why the same laboratory built a new chemical series around a boronic acid group that improved metabolic stability in laboratory assays. SLU-PP-915 came out of that series, and a 2026 paper in the Journal of Pharmacology and Experimental Therapeutics reports it as orally active. The two compounds are not interchangeable, and a product naming only the SLU-PP prefix does not establish which one it contains.
Because no curated registry pairs a CAS number with this structure. A number circulates in supplier listings and appears as an uncurated synonym on the compound's PubChem record, but there is no FDA substance registry entry for it and it does not appear in CAS Common Chemistry. PeptideScouter leaves the field empty rather than publish a number it cannot verify, and checks identity against the molecular formula C17H13BFNO3S and the PubChem compound record instead.
No. The published record is cell-culture and animal work, beginning with the 2023 European Journal of Medicinal Chemistry paper that identified the compound and extending to a 2026 report of oral activity in the Journal of Pharmacology and Experimental Therapeutics. ClinicalTrials.gov carried no registered study of the compound when read in November 2026, and Drugs@FDA lists no approved product containing it. A 2026 anti-doping laboratory study examined how the compound is broken down by human liver preparations in vitro, which is laboratory work rather than a human trial.
Because a per-milligram price is computed only for vials sized in milligrams, where the listing is a single mass of material. SLU-PP-915 is sold here as capsules, which are indexed with their prices but excluded from per-milligram comparisons, since a capsule listing is a count of units rather than one vial of material.
SLU-PP-915 is sold by 4 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 4 indexed research peptide vendors currently have SLU-PP-915 in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing SLU-PP-915 publish a PeptideScouter code, worth 10% to 15% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
4 research peptide vendors currently list SLU-PP-915 on PeptideScouter. We track 4 listings across size and kit variants.
